Merz Pharma Group (Frankfurt am Main) today announced that it has acquired the Swiss pharmaceutical company Neocutis S.A. The acquisition of the company`s cosmeceutical skin care business strengthens Merz`s market position in the field of aesthetic dermatology.
“Neocutis is an innovative company with an excellent presence on the U.S. market, and a promising potential for development,” said Philip Burchard, CEO of Merz Pharma. “This transaction is an important step to expand our U.S. business, as Neocutis products are an excellent addition to our own aesthetics portfolio.” The products are particularly used as preand post-treatments to aesthetic procedures.
The acquisition of Neocutis reflects the company’s strategy to establish itself as a leader in the field of medical and aesthetic dermatology. The U.S. is the most important market for Merz. Merz North America is an important player in aesthetics and medical dermatology, offering a wellbalanced range of products for minimally invasive treatments, including the dermal fillers Radiesse® and Belotero®, the neurotoxin Xeomin®, a product for the treatment of varicose veins, as well as products for the treatment of scars and fungal skin diseases.
Neocutis S.A. was founded in February 2003 as a spin-off of the medical faculty of the Lausanne University Clinic, Switzerland. The privately owned company with headquarters in Pully (Switzerland) develops and distributes innovative products for aesthetic dermatology (anti-aging, pigmentation problems, sun protection). The U.S. is the main market. Since the company entered the market in 2009, it has recorded strong annual growth. The anti-aging line is one of the products with the highest recorded turnover.